1,103 reports of this reaction
2.4% of all MIDAZOLAM HYDROCHLORIDE reports
#5 most reported adverse reaction
SEIZURE is the #5 most commonly reported adverse reaction for MIDAZOLAM HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 1,103 FDA adverse event reports linking MIDAZOLAM HYDROCHLORIDE to SEIZURE. This represents approximately 2.4% of all 46,685 adverse event reports for this drug.
Patients taking MIDAZOLAM HYDROCHLORIDE who experience seizure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEIZURE is a less commonly reported adverse event for MIDAZOLAM HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to seizure, the following adverse reactions have been reported for MIDAZOLAM HYDROCHLORIDE:
The following drugs have also been linked to seizure in FDA adverse event reports:
SEIZURE has been reported as an adverse event in 1,103 FDA reports for MIDAZOLAM HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEIZURE accounts for approximately 2.4% of all adverse event reports for MIDAZOLAM HYDROCHLORIDE, making it a notable side effect.
If you experience seizure while taking MIDAZOLAM HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.